VXRT_OUT_1 [2025-04-28 07:05:34 -0400] 5448 Bytes | 1547 tokens | Cum: 1547 tkns (19.34% of 8k)
==========================================================================

Alright, let’s light it up, because it's 7:05 AM on Mon Apr 28, 2025, and I'm charging into Vaxart (VXRT), popping from $0.3600 to $0.4080. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Vaxart (VXRT)
IPO: 1990-03-26 (35 Years Ago)
Market Cap: $75,177,661
Shares Outstanding: 228,210,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Here’s a list of headlines for Vaxart:

Apr-16-25 08:00AM - Vaxartto Present at World Vaccine Congress Washington 2025 on April 23
Mar-27-25 08:00AM - Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar-21-25 07:49AM - Q4 2024 Vaxart Inc Earnings Call
Mar-21-25 07:49AM 03:04AM - Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ...
Mar-20-25 06:25PM - Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript
Mar-20-25 06:25PM 05:15PM - VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
Mar-20-25 06:25PM 04:01PM - Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
Mar-20-25 06:25PM 10:00AM - Here are the major earnings after the close today
Mar-19-25 05:35PM - Vaxart FY 2024 Earnings Preview
Mar-13-25 08:00AM - Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
Mar-11-25 08:00AM - Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
Mar-05-25 04:05PM - Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults
Jan-28-25 08:00AM - Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors
Jan-14-25 08:00AM - Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs
Jan-13-25 07:55PM - Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
Dec-28-24 09:30AM - Vaxart project agreement change ups funding for oral COVID vaccine candidate
Dec-02-24 04:01PM - Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Nov-19-24 08:00AM - Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov-14-24 02:14AM - Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ...
Nov-13-24 05:20PM - VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
Nov-13-24 05:20PM 04:01PM - Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
Nov-07-24 08:00AM - Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-13T12:00:00Z - Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
B2 - 2024-06-17T20:32:16Z - Vaxart Stock Is Moving Higher After The Bell: What's Going On?
B3 - 2024-06-17T20:05:00Z - Vaxart Provides Business Update
B4 - 2024-06-13T23:07:00Z - Vaxart Announces $40 Million Underwritten Offering of Common Stock
B5 - 2024-06-13T20:15:00Z - Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
B6 - 2024-05-23T20:01:00Z - Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Vaxart (VXRT).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

VXRT_OUT_3 [2025-04-28 07:05:34 -0400] 1185 Bytes | 288 tokens | Cum: 1837 tkns (22.96% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Vaxart Stock Is Moving Higher After The Bell: What's Going On?**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/general/biotech/24/06/39366693/vaxart-stock-is-moving-higher-after-the-bell-whats-going-onVaxart Inc (NASDAQ:VXRT) shares are trading higher in Monday’s after-hours session after the company provided business and cash runway updates.
What Happened: Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company’s cash runway into 2026.
“The past week was especially important for Vaxart, because the combination of receiving one of the largest Project NextGen awards from BARDA and closing our $40 million financing from leading ...Full story available on Benzinga.com

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VXRT_OUT_5 [2025-04-28 07:05:35 -0400] 944 Bytes | 292 tokens | Cum: 2131 tkns (26.64% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T09:00:20Z - Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?...
A2 - 2025-04-16T12:29:54Z - Vaxartto Present at World Vaccine Congress Washington 2025 on April 23 | Taiwan News | Apr. 16, 2025...
A3 - 2025-04-16T12:17:13Z - Vaxartto Present at World Vaccine Congress Washington 2025 on April 23...
A4 - 2025-04-10T11:50:23Z - Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average - Here's What Happened...
A5 - 2025-03-31T05:17:05Z - B. Riley Issues Positive Outlook for Vaxart Earnings...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

VXRT_OUT_7 [2025-04-28 07:05:36 -0400] 1181 Bytes | 346 tokens | Cum: 2479 tkns (30.99% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?**Date: 2025-04-24Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/vaxart-nasdaqvxrt-stock-price-crosses-below-200-day-moving-average-should-you-sell-2025-04-22/Vaxart, Inc. (NASDAQ:VXRT - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.63 and traded as low as $0.31. Vaxart shares last traded at $0.32, with a volume of 1,136,429 shares.

Separately, B. Riley lowered their price target on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a research note on Thursday, March 27th.

Check Out Our Latest Research Report on Vaxart

The stock has a market capitalization of $72.59 million, a p

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VXRT_OUT_9 [2025-04-28 07:05:37 -0400] 1181 Bytes | 318 tokens | Cum: 2799 tkns (34.99% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): rice-to-earnings ratio of -0.78 and a beta of 1.57. The firm has a fifty day moving average of $0.48 and a 200-day moving average of $0.63.

Vaxart (NASDAQ:VXRT - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.05. The firm had revenue of $15.19 million for the quarter, compared to analysts' expectations of $15.68 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. As a group, research analysts forecast that Vaxart, Inc. will post -0.39 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Graham Capital Management L.P. grew its holdings in shares of Vaxart by 155.8% during the fourth quarter. Graham Capital Management L.P. now

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VXRT_OUT_11 [2025-04-28 07:05:38 -0400] 1181 Bytes | 309 tokens | Cum: 3110 tkns (38.88% of 8k)
==========================================================================

Showing A1 (chunk 3 of 5): owns 53,331 shares of the biotechnology company's stock worth $35,000 after buying an additional 32,482 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in Vaxart by 140.9% in the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 35,213 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Vaxart by 48.6% during the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock worth $50,000 after purchasing an additional 24,803 shares during the period. Bank of America Corp DE boosted its holdings in shares of Vaxart by 10.8% during the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 17,942 shares during the last qu

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VXRT_OUT_13 [2025-04-28 07:05:38 -0400] 1181 Bytes | 281 tokens | Cum: 3393 tkns (42.41% of 8k)
==========================================================================

Showing A1 (chunk 4 of 5): arter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Vaxart in the fourth quarter valued at $129,000. Institutional investors and hedge funds own 18.05% of the company's stock.

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VXRT_OUT_15 [2025-04-28 07:05:39 -0400] 1113 Bytes | 242 tokens | Cum: 3637 tkns (45.46% of 8k)
==========================================================================

Showing A1 (chunk 5 of 5): alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Vaxart, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.

While Vaxart currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VXRT_OUT_17 [2025-04-28 07:05:40 -0400] 1095 Bytes | 298 tokens | Cum: 3937 tkns (49.21% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S8 - 2025-03-21 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 21, 2025, Vaxart, Inc. (the Company) entered into an At the Market Offering Agrmt (the ATM Agrmt) with Citizens JMP Securities, LLC (Citizens) and B. Riley Securities, Inc. (B. Riley and, together with Citi...

S9 - 2025-03-20 8-K Item 2.02

Results of Oper and Fin Cond.

On March 20, 2025, Vaxart, Inc. (the Company) issued a press release (the Press Release) announcing its financial results for the year ended December 31, 2024. A copy of the Press Release is attached to this Curr Rep...

S10 - 2025-03-20 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the other sections of this Annual Report, including our c...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

VXRT_OUT_19 [2025-04-28 07:05:40 -0400] 1181 Bytes | 295 tokens | Cum: 4234 tkns (52.92% of 8k)
==========================================================================

Showing S8 (chunk 1 of 4): S8:
Item 1.01. Entry into a Material Definitive Agreement.

On March 21, 2025, Vaxart, Inc. (the Company) entered into an At the Market Offering Agreement (the ATM Agreement) with Citizens JMP Securities, LLC (Citizens) and B. Riley Securities, Inc. (B. Riley and, together with Citizens, the Managers), pursuant to which the Company may offer and sell, from time to time through the Managers, shares of the Companys common stock, par value $0.0001 per share (the Common Stock), having an aggregate offering price of up to $50 million (the Shares). The Shares will be sold pursuant to an effective registration statement on Form S-3 (Registration Statement No. 333-270671), as previously filed with the U.S. Securities and Exchange Commission (the Commission). The Company filed a prospectus supplement, dated March 21, 2025, with the Commission in connection with the offer and sale of the Shares.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VXRT_OUT_21 [2025-04-28 07:05:41 -0400] 1181 Bytes | 261 tokens | Cum: 4497 tkns (56.21% of 8k)
==========================================================================

Showing S8 (chunk 2 of 4):
Under the ATM Agreement, the Managers may sell the Shares by any method permitted by law and deemed to be an at the market offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the Securities Act), including sales made directly on The Nasdaq Capital Market, on any other existing trading market for the Common Stock, or to or through a market maker. In addition, under the ATM Agreement, the Managers may sell the Shares in privately negotiated transactions with the Companys consent. Under certain circumstances, the Company may instruct the Managers not to sell the Shares if the sales cannot be effected at or above the price designated by the Company from time to time.

The Company is not obligated to make any sales of the Shares under the ATM Agreement. The ATM Agreement may be terminated by the Company at any time upon three business days prior written

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VXRT_OUT_23 [2025-04-28 07:05:41 -0400] 1181 Bytes | 251 tokens | Cum: 4750 tkns (59.38% of 8k)
==========================================================================

Showing S8 (chunk 3 of 4): notice to the Managers, by the Managers at their discretion, or as otherwise permitted in the ATM Agreement.

The ATM Agreement contains customary representations, warranties and agreements by the Company, and customary indemnification and contribution rights and obligations of the parties. The Company will pay the Managers a placement fee of up to 3% of the gross sale price from each sale of the Shares. The Company will also reimburse the Managers for certain specified expenses in connection with entering into the ATM Agreement, and at each Representation Date (as defined in the ATM Agreement) in connection with ongoing diligence arising from the transactions contemplated by the ATM Agreement.

The ATM Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K, and the description of the terms of the ATM Agreement is qualified in its entirety by reference to such exhibit. A co

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VXRT_OUT_25 [2025-04-28 07:05:42 -0400] 793 Bytes | 189 tokens | Cum: 4941 tkns (61.76% of 8k)
==========================================================================

Showing S8 (chunk 4 of 4): py of the opinion of Thompson Hine LLP relating to the legality of the issuance and sale of the Shares is attached as Exhibit 5.1 hereto.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VXRT_OUT_27 [2025-04-28 07:05:48 -0400] 7234 Bytes | 2057 tokens | Cum: 7002 tkns (87.52% of 8k)
==========================================================================

This is our set of metrics for Vaxart.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-------------------------+
| Volume: 2,114,312 | Perf Month: -13.74% | Option/Short: Yes / Yes | Sales Y/Y TTM: 288.94% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 1.80M | Perf Quarter: -48.96% | Short Float: 5.91% | ROE: -114.71% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 1.15 | Index: - | Short Ratio: 7.29 | ROI: -89.18% |
+-------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 51.03 | Market Cap: 91.44M | Short Interest: 13.16M | Sales Surprise: -26.85% |
+-------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.04 | Shs Outstand: 227.77M | Beta: 1.29 | EPS Surprise: 60.00% |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 13.61% | Shs Float: 222.57M | Sales Q/Q: 367.95% | P/E: - |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -14.97% | Inst Own: 19.94% | Sales past 5Y: 1372.05% | Earnings: Mar 20 AMC |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -40.28% | Insider Own: 2.47% | Employees: 115 | |
+-------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 16.52% | Insider Trans: 0.00% | Debt/Eq: 0.40 | |
+-------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by Vaxart officers or majority shareholders (if available).

Inside Trans: Vaxart, Inc. (VXRT) by Tucker Sean (SVP, Chief Scientific Officer) on 2025-03-28
- Common Stock: 3913 shares at $0.4212 (D)

Inside Trans: Vaxart, Inc. (VXRT) by Cummings James F. (Chief Medical Officer) on 2025-03-28
- Common Stock: 3292 shares at $0.4212 (D)

Inside Trans: Vaxart, Inc. (VXRT) by Berg Edward B (SVP, General Counsel) on 2025-03-24
- Common Stock: 406000 shares at $0 (D)
- Stock Option (right to buy): 610000 shares at $0 (D)
- Stock Option (right to buy): 50000 shares at $0 (D)

Inside Trans: Vaxart, Inc. (VXRT) by Cummings James F. (Chief Medical Officer) on 2025-03-24
- Common Stock: 406000 shares at $0 (D)
- Stock Option (right to buy): 610000 shares at $0 (D)
- Stock Option (right to buy): 50000 shares at $0 (D)

Inside Trans: Vaxart, Inc. (VXRT) by Lee Phillip E (Chief Financial Officer) on 2025-03-24
- Common Stock: 406000 shares at $0 (D)
- Stock Option (right to buy): 610000 shares at $0 (D)

Inside Trans: Vaxart, Inc. (VXRT) by Tucker Sean (SVP, Chief Scientific Officer) on 2025-03-24
- Common Stock: 406000 shares at $0 (D)
- Stock Option (right to buy): 610000 shares at $0 (D)

Inside Trans: Vaxart, Inc. (VXRT) by Lo Steven (President, Chief Exec Officer) on 2025-03-24
- Common Stock: 1405000 shares at $0 (D)
- Stock Option (right to buy): 2108000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 28700000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -66948000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.4007
Average Volume: 1832153.16
30-Day High: 0.407
30-Day Low: 0.3065

[Detailed Financials: TTM 2024]
- Total Assets: $166,389,000.00
- Total Liabilities: $107,464,000.00
- Total Equity: $58,925,000.00
- Current Assets: $68,260,000.00
- Current Liabilities: $90,878,000.00

[Income Statement: TTM 2024]
- Revenue: $28,700,000.00
- Net Income: $-66,948,000.00
- Gross Profit: N/A
- Operating Income: $-66,293,000.00
- Earnings Per Share (EPS): -0.33

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-9,526,000.00

[Detailed Financials: FY 2024]
- Total Assets: $166,389,000.00
- Total Liabilities: $107,464,000.00
- Total Equity: $58,925,000.00
- Current Assets: $68,260,000.00
- Current Liabilities: $90,878,000.00

[Income Statement: FY 2024]
- Revenue: $28,700,000.00
- Net Income: $-66,948,000.00
- Gross Profit: N/A
- Operating Income: $-66,293,000.00
- Earnings Per Share (EPS): -0.33

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-9,526,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Vaxart (VXRT).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Vaxart.

2) MARKET_SCORE[]
This conversation was initiated because VXRT is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for VXRT.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, VXRT could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect VXRT to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Vaxart.

11) ETHICAL_RATING[]
Rate Vaxart’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Vaxart.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

VXRT_IN_29 [2025-04-28 07:05:49 -0400] 126 Bytes | 29 tokens | Cum: 7255 tkns (90.69% of 8k)
==========================================================================

====================================
[2025-04-28 07:05:49] # Analysis Completed
Elapsed Time: 15.99 seconds